264 related articles for article (PubMed ID: 25122066)
1. Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.
Babcook MA; Shukla S; Fu P; Vazquez EJ; Puchowicz MA; Molter JP; Oak CZ; MacLennan GT; Flask CA; Lindner DJ; Parker Y; Daneshgari F; Gupta S
Mol Cancer Ther; 2014 Oct; 13(10):2288-302. PubMed ID: 25122066
[TBL] [Abstract][Full Text] [Related]
2. Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.
Babcook MA; Sramkoski RM; Fujioka H; Daneshgari F; Almasan A; Shukla S; Nanavaty RR; Gupta S
Cell Death Dis; 2014 Nov; 5(11):e1536. PubMed ID: 25412314
[TBL] [Abstract][Full Text] [Related]
3. Ser-486/491 phosphorylation and inhibition of AMPKα activity is positively associated with Gleason score, metastasis, and castration-resistance in prostate cancer: A retrospective clinical study.
Babcook MA; Akgul M; Margevicius S; MacLennan GT; Fu P; Abouassaly R; Gupta S
Prostate; 2018 Jul; 78(10):714-723. PubMed ID: 29577356
[TBL] [Abstract][Full Text] [Related]
4. Statin derivatives as therapeutic agents for castration-resistant prostate cancer.
Ingersoll MA; Miller DR; Martinez O; Wakefield CB; Hsieh KC; Simha MV; Kao CL; Chen HT; Batra SK; Lin MF
Cancer Lett; 2016 Dec; 383(1):94-105. PubMed ID: 27687622
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells.
Mayer MJ; Klotz LH; Venkateswaran V
Anticancer Res; 2017 Dec; 37(12):6601-6607. PubMed ID: 29187435
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.
Mayer MJ; Klotz LH; Venkateswaran V
J Urol; 2017 Apr; 197(4):1068-1075. PubMed ID: 27984108
[TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
[TBL] [Abstract][Full Text] [Related]
9. Effect of simvastatin on castration-resistant prostate cancer cells.
Kim JH; Cox ME; Wasan KM
Lipids Health Dis; 2014 Mar; 13():56. PubMed ID: 24666612
[TBL] [Abstract][Full Text] [Related]
10. Concurrent treatment with simvastatin and NF-κB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-κB/LIN28/let-7 miRNA signaling pathway.
Kang M; Lee KH; Lee HS; Jeong CW; Ku JH; Kim HH; Kwak C
PLoS One; 2017; 12(9):e0184644. PubMed ID: 28910332
[TBL] [Abstract][Full Text] [Related]
11. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
12. Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Chi KN; Higano CS; Blumenstein B; Ferrero JM; Reeves J; Feyerabend S; Gravis G; Merseburger AS; Stenzl A; Bergman AM; Mukherjee SD; Zalewski P; Saad F; Jacobs C; Gleave M; de Bono JS
Lancet Oncol; 2017 Apr; 18(4):473-485. PubMed ID: 28283282
[TBL] [Abstract][Full Text] [Related]
13. The Effects and Mechanism of YK-4-279 in Combination with Docetaxel on Prostate Cancer.
Yu L; Wu X; Chen M; Huang H; He Y; Wang H; Li D; Du Z; Zhang K; Goodin S; Zheng X
Int J Med Sci; 2017; 14(4):356-366. PubMed ID: 28553168
[No Abstract] [Full Text] [Related]
14. MK591, a second generation leukotriene biosynthesis inhibitor, prevents invasion and induces apoptosis in the bone-invading C4-2B human prostate cancer cells: implications for the treatment of castration-resistant, bone-metastatic prostate cancer.
Sarveswaran S; Ghosh R; Morisetty S; Ghosh J
PLoS One; 2015; 10(4):e0122805. PubMed ID: 25875826
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Araujo JC; Trudel GC; Saad F; Armstrong AJ; Yu EY; Bellmunt J; Wilding G; McCaffrey J; Serrano SV; Matveev VB; Efstathiou E; Oudard S; Morris MJ; Sizer B; Goebell PJ; Heidenreich A; de Bono JS; Begbie S; Hong JH; Richardet E; Gallardo E; Paliwal P; Durham S; Cheng S; Logothetis CJ
Lancet Oncol; 2013 Dec; 14(13):1307-16. PubMed ID: 24211163
[TBL] [Abstract][Full Text] [Related]
16. Activation of AMPKα mediates additive effects of solamargine and metformin on suppressing MUC1 expression in castration-resistant prostate cancer cells.
Xiang S; Zhang Q; Tang Q; Zheng F; Wu J; Yang L; Hann SS
Sci Rep; 2016 Nov; 6():36721. PubMed ID: 27830724
[TBL] [Abstract][Full Text] [Related]
17. Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies.
Abdel-Rahman O
Clin Genitourin Cancer; 2019 Feb; 17(1):e104-e112. PubMed ID: 30341029
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
Park SE; Kim HG; Kim DE; Jung YJ; Kim Y; Jeong SY; Choi EK; Hwang JJ; Kim CS
Invest New Drugs; 2018 Apr; 36(2):195-205. PubMed ID: 29110173
[TBL] [Abstract][Full Text] [Related]
19. The effects of metformin and simvastatin on the growth of LNCaP and RWPE-1 prostate epithelial cell lines.
Pennanen P; Syvälä H; Bläuer M; Savinainen K; Ylikomi T; Tammela TLJ; Murtola TJ
Eur J Pharmacol; 2016 Oct; 788():160-167. PubMed ID: 27341997
[TBL] [Abstract][Full Text] [Related]
20. Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis.
O'Brien AJ; Villani LA; Broadfield LA; Houde VP; Galic S; Blandino G; Kemp BE; Tsakiridis T; Muti P; Steinberg GR
Biochem J; 2015 Jul; 469(2):177-87. PubMed ID: 25940306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
